

Friday, May 31, 2019

Dear Valued Customer,

As one of the leading providers of oncology testing services, Quest Diagnostics is committed to helping you and your patients know more sooner, with technological innovations driven by the latest medical findings.

We are proud to announce **Oncomine™ Dx Target Test (NGS)** is now available at Quest PhenoPath. This is PhenoPath's first-ever Next Generation Sequencing (NGS) assay.

The Oncomine Dx Target Test is a qualitative in vitro diagnostic test that uses targeted high throughput, parallel sequencing technology to detect single nucleotide variants (SNVs), deletions in 23 genes from DNA, and fusions in ROS1 from RNA. All this information is obtained from an FFPE sample and can be run from as little as 10ng of DNA.

The test is indicated to aid in selecting non-small cell lung cancer (NSCLC) patients for the targeted therapies below:

- BRAF V600E mutation: TAFINLAR® (dabrafenib) in combination with MEKINIST® (trametinib)
- ROS1 fusion: XALKORI® (crizotinib)
- EGFR L858R mutation and Exon 19 deletions: IRESSA® (gefitinib)

The Oncomine Dx Target Test report includes the relevant drug for the companion diagnostic and mutation information for the additional genes in an FDA-approved template.

Ordering information

Test code	Test name	CPT code*	Turnaround time
36442	Oncomine™ Dx Target Test	0022U	10 - 14 days

*The CPT codes are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

To learn more about Oncomine Dx Target Test, speak with your Quest Diagnostics sales representative, call 1.888.92.PHENO (1.888.927.4366), or visit PhenoPath.com

Sincerely,



Steven J. Kussick, MD, PhD
Medical Director